Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis

Yang D. Teng, Howard Choi, Wenzheng Huang, Renna C. Onario, Walter R. Frontera, Evan Y. Snyder, Sunil Sabharwal

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


We investigated the effects of clenbuterol, a β2-adrenoceptor agonist with known anabolic and neuroprotective properties, on G93A-SOD1 mice, a transgenic murine model of familial amyotrophic lateral sclerosis (ALS). Relative to saline-treated vehicle controls (0.2 ml/kg/day; i.p.), early pathologic G93A-SOD1 mice treated with clenbuterol (1.5 mg/kg/day; i.p.) demonstrated a delayed onset of hindlimb signs as measured by rotarod performance, slowed disease progression, as well as trends toward mitigated losses of lumbar motoneurons and body weight. Responses in female G93A-SOD1 mice were favorable to those of males, suggesting synergistic effects between clenbuterol and sex-specific factors. Overall, our data suggest that clenbuterol offers therapeutic effects on ALS-related neuromuscular degeneration.

Original languageEnglish
Pages (from-to)155-158
Number of pages4
JournalNeuroscience Letters
Issue number1-2
StatePublished - 10 Apr 2006
Externally publishedYes


  • Amyotrophic lateral sclerosis
  • Clenbuterol
  • Dimorphism
  • G93A-SOD1 transgenic mice
  • Spinal cord


Dive into the research topics of 'Therapeutic effects of clenbuterol in a murine model of amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this